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Abstract: There are well-documented disparities in vaccination rates between different socioeco-
nomic and racial/ethnic groups in the United States. These disparities persist in spite of an overall
increase in vaccination rates during the last decade and the implementation of several interven-
tions that have aimed to increase vaccination rates in disadvantaged groups. Although many inter-
ventions are efficacious at improving vaccination rates under trial conditions, these interventions
when extended to the general population frequently do not appreciably improve its health. Ex-
planations for this limited intervention efficiency include poor adherence to protocols in real life
versus idealized trial situations, changes in baseline so that the trial conditions are no longer repli-
cable, and the contribution of other community-level factors that make it difficult to extend the
trial methods to other communities. Multilevel community intervention trials recognize and ad-
dress the multiple competing forces that shape the health of the population in cities and have the
potential to increase vaccination rates among minorities and marginalized groups. Key words:
health disparities, interventions, multilevel, vaccination
THERE are well-documented disparities invaccination rates between different socio-
economic and racial/ethnic groups in the
United States (Centers for Disease Control and
Prevention [CDC], 1995, 2001). These dis-
parities persist in spite of an overall increase
in vaccination rates during the last decade
and the implementation of several interven-
tions that have aimed to increase vaccina-
tion rates in disadvantaged groups. For ex-
ample, although a number of interventions
have aimed to increase vaccination cover-
age among Blacks, national vaccination rates
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for influenza among Whites remain approxi-
mately one and a half times higher than they
are among Blacks (CDC, 2001). This article
discusses why interventions that are effica-
cious under trial conditions may fail to be
effective at the population level, and how
multilevel interventions may overcome some
of these barriers and offer an innovative ap-
proach to reducing the disparities in vaccina-
tion rates in the United States.
RACIAL/ETHNIC DISPARITIES IN
VACCINATION COVERAGE IN THE
UNITED STATES
For the last century, disparities in health
outcomes have existed in the United States
between racial/ethnic groups, between socio-
economic groups, and between groups at
different levels of social advantage and
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disadvantage (Adler & Ostrove, 1999; CDC,
2002; Gornick et al., 1996; Hargraves, 2001;
Janes et al., 1999; Link & Phelan, 1996;
Marmot, 1999; National Institutes of Health
[NIH], 2002). Health disparities persist de-
spite a national agenda directed toward min-
imizing health differences between groups,
and, in the instance of many diseases, substan-
tial effort aimed at improving the health of
disadvantaged populations (CDC, 2002; NIH,
2002).
There are well-documented racial/ethnic
disparities in vaccination rates in the United
States. Focusing on vaccination rates for in-
fluenza as an example, in 1993, the Medicare-
paid influenza vaccination rate among Whites
was 37% compared to 17% among Blacks
(CDC, 1995). Vaccination rates for influenza
increased substantially throughout the United
States in the 1990s, from 33% overall in 1989
to 66% in 1999 nationally among persons aged
65 or older (CDC, 1995, 2001). In 1999, in-
fluenza vaccination coverage was the high-
est it had ever been among Blacks, Hispanics,
and Whites. Vaccination levels among Blacks
and Hispanics, however, continued to be
lower than among Whites (CDC, 2001). The
influenza vaccination rate overall was 68%
among Whites aged 65 or older, 55% among
Hispanics, and 50% among Blacks. A study
that used data from the 1996 Medical Expen-
diture Panel Survey compared influenza vacci-
nation levels of different racial/ethnic groups
among 2309 persons aged 65 or older (Marin
et al., 2002). In this panel, 68.0% of Whites,
61.7% of Hispanics, and 47.3% of Blacks had
current influenza vaccination. Adjustment for
potential confounders, including health risk,
age distribution, health status, family size, am-
bulatory care visits, and poverty level, failed to
change this difference substantially. In fully ad-
justed multivariable logistic regression mod-
els, Blacks remained half as likely as Whites
to have current influenza vaccination (Marin
et al., 2002).
LOW VACCINATION RATES IN
DISADVANTAGED GROUPS
Although most documented disparities in
health in the United States pertain to differ-
ences across racial/ethnic groups, socioeco-
nomic status and social disadvantage have also
been shown to be associated with lower vac-
cination rates. For example, although all of
the goals of the Childhood Vaccination Initia-
tive (an intensive program to increase vaccina-
tion coverage among preschool-age children
and eliminate vaccine-preventable diseases
nationally) were met among Whites by 1996,
3 of the 5 coverage goals were not met
for children living below the poverty level
(CDC, 1997). From 1996 to 1999, the National
Vaccination Survey (a phone survey of 28
US urban areas) found that vaccination cov-
erage was consistently lower among children
living below the poverty level (Klevens &
Luman, 2001). Markers of socioeconomic sta-
tus/social disadvantage that are associated
with lower vaccination rates include not liv-
ing in a self-owned residence, unemployment,
having chronic illness, having less than a
high school education, and immigration status
(Mieczkowski & Wilson, 2002; Nichol et al.,
1996; Petersen et al., 1999; Vryheid, 2001).
Marginalized groups have been shown to
have particularly low vaccination rates. For
example, hepatitis B vaccine had been avail-
able for a decade when a survey of nearly 3000
injection drug users in Baltimore showed that
fewer than 10% of injection drug users had
been vaccinated (Levine et al., 1995) de-
spite substantial interest in health and vaccina-
tion in this population (Harrison et al., 1995;
Vlahov et al., 1994). In one survey among
immigrants and refugees, vaccination series
completion rates ranged from 33% to 60%
among children, substantially lower than com-




During the last decade, the overall increase
in vaccination coverage nationwide has been
attributed to several factors, including greater
acceptance of preventive medical services
by practitioners, new information regarding
the effectiveness and safety of vacciness,
initiation of Medicare reimbursement for a
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number of vaccinations, and increased deliv-
ery and administration of vaccines by health-
care providers (Arden et al., 1986; Gross et al.,
1994; Mullooly et al., 1994; Patriarca et al.,
1985). At the national level, specific task
forces, such as The National Task Force on
Hepatitis B Vaccination, have focused on im-
proving the availability and delivery of vac-
cines through established systems of service
provision (Reilley, 2001).
At the local level, several innovative pro-
grams have shown successful increases in vac-
cination rates. In an assessment of different in-
terventions aimed at increasing vaccination of
children enrolled in the Special Supplemental
Food Program for Women, Infants, and Chil-
dren (WIC), children who were at sites where
escort to a nearby pediatrics clinic was ar-
ranged were 5.5 times more likely to be im-
munized, and those who were at sites with
voucher incentives were 2.9 times more likely
to be immunized than were children at sites
where passive referrals were provided (Birk-
head et al., 1995). Voucher incentives in WIC
participants have also been shown to increase
childhood vaccination in inner-city popula-
tions (Hoekstra et al., 1998). A randomized
controlled trial of an intervention that encour-
aged parents to vaccinate their children found
that children in the intervention group had
higher up-to-date vaccination (51% vs 39%)
than did children in the control group (Kempe
et al., 2001). In addition, media advertising
has been shown to be an effective tool
in increasing the acceptability of vaccina-
tion among minorities (Lashuay et al., 2000),
among gay men (Friedman et al., 2000), and
among children (Paunio et al., 1991). Vaccina-
tion rates have also been increased through
mobilization of community-based organiza-
tions. For example, in response to a well-
publicized low rate of measles-mumps-rubella
vaccination in New York State, a program that
mobilized community-based organizations to
enroll children was able to show that after 9
months of operation, 73% of children were
up-to-date for their vaccinations (Rosenberg
et al., 1995).
Although these programs are all large-
scale efforts, the success of relatively lim-
ited programs at increasing vaccination up-
take also has been documented (Minkovitz
et al., 2001). For example, there have been a
series of randomized trials to test methods to
enhance vaccination in hospital practice, in-
cluding phone outreach, education added to
visits, and hospital-based nurse outreach (eg,
Dey et al., 2001). Although these results have
shown only a moderate increase in vaccina-
tion, these results suggest that these methods
should be tested among those not already re-
ceiving routine care. Recognizing that many
disadvantaged populations do not have a usual
source of care, the emergency department is
frequently seen as a site for offering vaccina-
tion. In one study examining the feasibility of
pneumococcal vaccination through an emer-
gency department, of 1833 patient screening
encounters, 1493 were identified as high risk
and only 10% reported previous pneumococ-
cal vaccination. One thousand one hundred
seventy-three persons in this population were
vaccinated, with the authors concluding that
vaccination is both “necessary and feasible”
given the context of patients “with little ac-
cess to other vaccination services”(Slobodkin
et al., 1999). A similar study found that only
3% of identified high-risk patients present-
ing to an inner-city hospital were vaccinated
against Pneumococus and 18% had been vac-
cinated against influenza the previous year
(Slobodkin et al., 1998). Sixty-one percent
of high-risk patients with no contraindica-
tion to influenza vaccination were vaccinated
(Slobodkin et al., 1998). A few studies have
shown that special programs such as syringe
exchange programs also can be used suc-
cessfully to improve vaccination rates among
marginalized, hard-to-reach populations (Des
Jarlais et al., 2001; Stancliff et al., 2000).
Limitations
The success reported by individual pro-
grams aimed at improving vaccination cover-
age contrasts with the persistent disparities
in vaccination coverage between different
groups in the United States. For example, a re-
cent cohort study of 13,674 Black and White
Medicare beneficiaries with either managed
care or fee-for-service insurance found an
overall influenza coverage of 65.8%, and that
Whites were substantially more likely to be
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vaccinated than were Blacks (67.7% vs 46.1%)
(Schneider et al., 2001). Although persons en-
rolled in managed care were more likely than
those with fee-for-service insurance to receive
influenza vaccination, vaccination prevalence
among Whites was 18.6% higher than among
Blacks in the managed care group (Schneider
et al., 2001). There are several reasons why
disparities in vaccination coverage persist de-
spite intense efforts on the part of public
health practitioners and governmental institu-
tions. Three possible explanations include the
difficulty in expanding programs from a lim-
ited trial to a wide-scale intervention, changes
in baseline so that the trial conditions are
no longer replicable, and the contribution of
other community-level factors that make it dif-
ficult to extend the trial methods to other
communities. We discuss each of these in
turn.
Public health interventions, particularly in-
terventions that are rigorously evaluated and
eventually published in the peer-reviewed lit-
erature, rest on the implementation of proto-
cols to achieve the desired outcome. There-
fore, programs are carefully planned and re-
sources are appropriately diverted to ensure
that the intervention is implemented as
planned. As discussed above, in one program
aimed at improving vaccination coverage
among children enrolled in WIC, New York
State public health authorities designed an in-
tervention whereby an escort was provided to
take the child from the WIC site to a nearby
pediatric clinic for vaccination (Birkhead
et al., 1995). This intervention trial arm was
then compared to a control group whose par-
ticipants were passively referred to the clinic
for vaccination. The intervention group was
found to be more than 5 times more likely to
be immunized in this trial than was the control
group (Birkhead et al., 1995). In another in-
tervention discussed previously, provision of
pneumococcal vaccination to high-risk disad-
vantaged populations through an emergency
department was found to be feasible, and the
trial immunized more than a 1000 persons
in a 2-month period (Slobodkin et al., 1999).
The success of both these efforts, as does
the success of all other comparable interven-
tions, rests on the infrastructure developed to
successfully implement the intervention (eg,
investigators, program managers, nurses), on
the cooperation of other healthcare providers
(WIC clinic employees or emergency depart-
ment practitioners in these 2 examples), and
on the availability of resources to implement
the programs (eg, human resources to escort
children to vaccination clinics, financial re-
sources to pay extra staff).
Although efforts such as these are feasi-
ble in the short term, when their success de-
pends on dedicated investigators and public
health practitioners, they often fall short in
effectively improving vaccination rates in the
long term. Beyond the confines of the trial,
these interventions must be implemented sys-
tem wide to achieve sustainable population-
level change and the factors that have been
shown to be efficacious in the context of a lim-
ited trial must be replicated on a much larger
scale. Such an expansion of successful inter-
ventions, however, is often beyond the scope
of the public health practitioners who carried
out the initial intervention. Rather, such ex-
pansions of programs enter the realm of pol-
icy, at the local, state, or federal level. There-
fore, continuation of a successful program
to offer vaccination to disadvantaged popu-
lations through the emergency department
would require adaptation of multiple systems
to the program, including hospital commit-
ment to the program in the long term, sus-
tainable availability of vaccination resources,
and the cooperation of a number of institu-
tions governing the allocation of human re-
sources (eg, program management and ad-
ministration). Ultimately, competing interests
frequently result in a failure of expansion of
successful interventions to levels that could
achieve meaningful population-level change.
When programs are implemented on a broad
scale, their implementation is often compro-
mised, with specific elements of the suc-
cessfully implemented intervention altered
to make the program feasible in the long
term. Such compromises may have an unpre-
dictable effect on trials that had been effica-
cious under controlled conditions, but whose
effectiveness is untested on a larger scale.
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A second barrier frequently encountered in
the translation from controlled intervention
to wide-scale program implementation is the
fact that the conditions for which the inter-
vention was initially carefully designed are no
longer applicable in the larger population. In-
terventions are designed to account for con-
ditions prevailing at the time of program in-
ception. For example, an intervention aimed
at increasing vaccination awareness through
the mass media will be rooted in attitudes pre-
vailing toward vaccination at the time of pro-
gram design. It takes several years, however,
to go from program design to implementation,
to evaluation, and then to presentation of the
findings to a wider audience. It is frequently
the case that the conditions for which the in-
tervention was designed are no longer appli-
cable. In the context of an intervention that
makes use of the mass media, the proven effi-
cacy of a specific set of media images cannot
then be generalized to have widespread effec-
tiveness if the initial context for which the me-
dia images were created has now changed.
The observation that baseline conditions
for which interventions are developed may
change before there is an opportunity to ex-
tend the intervention to a larger scale is part
of a broader limitation of focused interven-
tions. Specifically, interventions are primarily
designed to focus on one aspect that is con-
sidered problematic. In the context of vac-
cination rates, interventions are designed to
overcome a factor that is considered to be
a barrier to successful vaccination. Factors
that influence access to care in general in-
clude having a regular source of care, socio-
economic status, and insurance status (Janes
et al., 1999; Lambrew et al., 1996). Specific
studies have shown that factors that affect
vaccination rates include attitudes and beliefs
about vaccination (Harrington et al., 1999;
Lewis-Parmar & McCann, 2002; Nichol et al.,
1992, 1996; Pearson & Thompson, 1994), at-
titudes about healthcare (Fowles & Beebe,
1998), past use of healthcare (Fiebach &
Viscoli, 1991; Pearson & Thompson, 1994),
knowledge of burden of the disease (San-
tibanez et al., 2002), cost as a primary bar-
rier to healthcare (Merkel & Caputo, 1994;
Richardson & Michocki, 1994), lack of trans-
portation (Ganguly et al., 1987), and vaccina-
tion delivery methods (Gyorkos et al., 1994).
As such, many interventions are designed to
target these factors. For example, some of
the interventions discussed above target ac-
cess to vaccination (eg, Birkhead et al., 1995),
attitudes about vaccination (e.g., Paunio
et al., 1991), and vaccination delivery (eg,
Slobodkin et al., 1998; Stancliff et al., 2000).
This focus on one (or at best a few) manipula-
ble barrier to vaccination often fails to recog-
nize the contribution of other factors, at the
individual or community level, that may inter-
act with the factor of interest and that may
also shape vaccination rates. Although an in-
tervention that focuses on improving vacci-
nation opportunities for disadvantaged pop-
ulations (through an emergency department
program or through a syringe exchange pro-
gram) may well successfully immunize such
populations, that intervention is grounded in
the circumstances of the time and place when
it was designed and implemented. As a result,
extension of the intervention methods to the
broader population or to a different popula-
tion at a different time may well not prove
effective.
The difficulties inherent in extending
demonstrably effective intervention trials to
the general population, although not neces-
sarily unique to vaccination interventions,
contribute to the ongoing disparities in vacci-
nation rates between different groups. These
difficulties, however, also suggest possible
solutions that may be incorporated into an
alternative method of designing interventions
that may address some of these problems. In
the next section, we discuss how multilevel
interventions can be designed to meet some
of these challenges, and as such have the
potential to improve disparities in vaccination




Multilevel approaches to interventions are
grounded in the social ecological theory.
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Briefly stated, the social ecological the-
ory holds that individual characteristics (eg,
precautionary behaviors like vaccination)
that have consequences such as disease or
health are shaped by the social environment
(Kaplan, 1999; Krieger, 1991; Susser & Susser,
1996). The social environment involves struc-
tural factors (eg, civic community, gov-
ernment), social characteristics (eg, social
norms), and processes (eg, diffusion of inno-
vation) that combine to shape individual char-
acteristics. Vaccination is only one example of
a public health goal that could benefit from
multilevel consideration. Figure 1 presents an
example of how a multilevel approach to vac-
cination intervention would consider the dif-
ferent levels of influence that determine vac-
cination rates in specific groups. First, at the
state level, regulation shapes the scope of ser-
vices covered by public health insurance (eg,
Medicaid) and barriers to access of these ser-
vices. Therefore, state-level factors are rele-
vant to the circumstance on which the pub-
lic health professional may wish to intervene.
Second, at the municipal level, distribution
of resources (eg, health clinics, health pro-
fessionals), community attitudes toward vac-
cination, and collective efficacy, that is, the
community’s ability to mobilize to obtain vac-
cination, may all affect the success of the
vaccination program. Third, at the individual
level, individual education and social circum-
Figure 1. Multilevel interventions to improve vaccination rates, an example. The examples provided at
each of the levels are for illustration purposes. There are several more variables that can be considered at
each level. Similarly, there are many other levels that can be important determinants of vaccination rates.
stances (eg, income, having children, social
supports) may influence whether an individ-
ual will be vaccinated.
Importantly, vaccination efforts that avoid
the complexity of barriers to vaccination and
of changing individual behavior are likely in-
sufficient for sustainable, long-term improve-
ment in vaccination rates and for minimizing
disparities in vaccination between different
racial/ethnic and socioeconomic groups.
These ongoing disparities, coupled with
the efforts that have been expended to im-
prove vaccination rates, suggest that moving
from an efficacious intervention to effective
population-level interventions requires a
recognition that interventions need to pro-
ceed simultaneously in multiple dimensions
at different levels. The traditional approach
to intervention research is to isolate and test
components (eg, media messages, insurance
financing strategies), ideally in randomized
controlled trials. The substantial barriers that
these interventions then face, however, in
being generalized to the broader population
suggest that early consideration of other fac-
tors that are important for translating the vac-
cination trial to a broader scale will likely be
more effective in the long term. Concurrent
with this view, recent reviews of intervention
studies have overwhelmingly concluded
that population-level intervention research
should include an expanded appreciation of
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the multiple levels of influence on health
behavior (Fortmann et al., 1995; Sorensen
et al., 1998).
Potential advantages
Multilevel approaches to vaccination ef-
forts have the potential to be an invaluable
addition to the intervention armamentarium
and to help address some of the limitations
faced in generalizing intervention trials. In
the context of vaccination, multilevel inter-
ventions must recognize that barriers to vac-
cination are neither independent of one an-
other nor from the community context within
which the barriers are observed. For exam-
ple, we can consider the challenge of in-
creasing vaccination rates and decreasing dis-
parities in vaccination rates in a particular
metropolitan area. Vaccination rates (overall
and within specific groups) are likely a prod-
uct of several factors as shown in Figure 1. As
discussed throughout this article, typical vac-
cination interventions have traditionally tar-
geted one facet that determines the likelihood
of vaccination. For example, an intervention
may work to increase access to vaccination
services (eg, reducing barriers to eligibility at
health clinics) or to improve attitudes toward
vaccination (eg, through media campaigns or
working with key community leaders). These
interventions may well prove successful and
increase vaccination rates in the community
of interest. Barriers to expanding this inter-
vention, however, may include difficulties in
sustaining the intervention after the interven-
tion trial has been completed, changes in
the baseline factors at other levels that make
the intervention trial itself obsolete, and chal-
lenges translating the intervention to diverse
communities where factors at the other levels
differ.
Multilevel interventions aim to address the
multiple determinants that can potentially
influence effective vaccination programs to
overcome some of these challenges. A mul-
tilevel intervention may include elements of
working with the state legislature to increase
the scope of services covered by public in-
surance, a media campaign to increase aware-
ness of the availability of these services and
to influence social norms about vaccination,
and a program that offers escorts to vacci-
nation clinics to persons with limited social
supports. In so doing, the multilevel interven-
tion addresses barriers to vaccination at mul-
tiple levels. Since they are implemented as
a comprehensive intervention strategy, multi-
level interventions have the potential to move
beyond the experimental trial phase and to
be relatively easily generalized to the popula-
tion after the formal trial phase is completed.
If implemented in an experimental fashion
(eg, through randomizing city or neighbor-
hood units in a trial), the multilevel inter-
vention trial can also provide empiric infor-
mation about the relative impact of each of
these levels that ultimately can guide future
interventions in different contexts. In addi-
tion, the multilevel intervention, sensitive to
community conditions and how they may
be changing, can also avoid the potential
for changing baseline conditions for which
the intervention was designed, making the
intervention obsolete by the time it is
completed. Community-based participatory
methods have emerged as among the more ef-
fective methods through which multilevel in-
terventions can become aware of community
conditions (see Israel et al., 1998, for a com-
prehensive review of community-based meth-
ods). Community-based methods incorporate
community members as an integral part of the
research and intervention team behind mul-
tilevel trials, making the intervention respon-
sive to community needs and to barriers that
may be faced in improving vaccination rates.
Community participation in the implementa-
tion of multilevel trials can bring light into fac-
tors that may otherwise not be apparent to
the public health practitioner. For example,
attitudes toward vaccination are often instru-
mental in shaping vaccination rates (Nichol
et al., 1996), and can be difficult to fully ap-
preciate for persons who are not community
members.
Limitations of multilevel interventions
Multilevel interventions face limitations,
some of which they share with all other
forms of vaccination interventions and some
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of which are particular to multilevel interven-
tions. First, multilevel interventions are lim-
ited, as are all other interventions, by the
scope of the intervention itself and by the
limited resources that may be available in the
posttrial period to generalize the implemen-
tation to a larger population. The scope of
the multilevel intervention (including both
the size of the population that is included
in the intervention and the number of lev-
els of influences that are intervened upon)
is ultimately limited by the availability of fi-
nancial and human resources. Implementa-
tion of multilevel trials requires careful super-
vision of standardized interventions at multi-
ple levels, effectively multiplying the amount
of work inherent in standard interventions
that target single levels of interest. Second, as
apparent in this discussion, multilevel inter-
ventions are uniquely resource-intensive dur-
ing their implementation. Although we are
not aware of any formal cost-benefit analysis
of multilevel interventions versus standard in-
terventions that have been published in the
peer-reviewed literature, it is plausible that
the benefits of multilevel interventions in the
short term, that is, greater population effi-
ciency that can be translated easily to other
communities and obviating the need for many
other ineffective standard interventions, and
in the long term, that is, through improving
health among populations that have histori-
cally borne a substantial burden of disease,
outweigh the upfront costs inherent in multi-
level interventions. Rigorous cost-benefit eval-
uation of multilevel trials is needed to shed
light on this point. Third, multilevel interven-
tion trials are complicated by methodologic
considerations that are unique to interven-
tion and analysis across levels. The design of
intervention trials at multiple levels requires
the enrollment of sufficient trial participants,
both at the individual level and at the group
level. As such, for the effects of multiple lev-
els to be detected, sufficient groups (eg, com-
munities, cities) must be included in the trial
to provide sufficient statistical power for the
detection of meaningful effect sizes. Although
some authors have now begun to provide cal-
culations that can guide these sample size es-
timates (cf. Hoover, 2002), the science of mul-
tilevel interventions remains in its infancy. Im-
portantly, the fact that such trials require the
inclusion of multiple groups of interest means
that a larger sample size than that which
would be required for standard interventions
is necessary for multilevel interventions, with
important resource implications as previously
discussed.
Thus far, there have been very few multi-
level interventions implemented, evaluated,
and described in the peer-reviewed literature
(see, eg, Komro et al. 2001; MacLean et al.,
2003) and none that we are aware of that
pertain specifically to vaccination. As such,
ideas about the implementation of multilevel
interventions, their practical limitations, and
their potential remain untested. It is worth
noting that some of the more successful vacci-
nation programs in history can be construed
as multilevel programs, even if they were not
explicitly formulated as such. For example,
the successful global smallpox eradication
campaign engaged multiple federal systems,
health systems, local attitudes, and individual
barriers to access to vaccination to deliver
vaccines to those at risk of smallpox expo-
sure worldwide (Henderson, 1987). Over the
last decade, there has been a tremendous in-
crease in multilevel analysis (Diez-Roux, 2002;
O’Campo, 2003), primarily using extant data,
which has demonstrated the importance of
factors at multiple levels in shaping health
behavior and individual disease. Both formal
multilevel interventions currently underway
in many centers throughout the United States
and future publications have the potential to
advance our understanding of multilevel inter-
ventions and the roles they can play in improv-
ing health outcomes in different groups.
CONCLUSIONS
Persistent disparities in vaccination rates
between racial/ethnic and socioeconomic
groups, despite substantial federal and local
efforts at minimizing disparities, suggest that
the traditional approaches to improving vac-
cination coverage may be insufficient. There
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are several reasons why interventions that are
efficacious in the context of a trial may be
difficult to translate effectively to the general
population. Multilevel interventions offer one
way of overcoming some of these challenges.
By recognizing that factors at multiple lev-
els may influence the barriers to vaccination
faced by specific populations, multilevel inter-
ventions may improve vaccination rates in the
general population in the long term, and, con-
sequently, contribute to minimizing dispari-
ties in health.
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